ABSTRACT

How can biotechnology companies accelerate small molecule drug discovery while maintaining scientific quality? This practical guide explores hit-to-lead optimization, outsourcing strategies, partner selection, and the capabilities that help transform promising hits into development-ready lead candidates.

Outsourcing Small Molecule Drug Discovery from Hit to Lead: What Really Drives Success?

Hit-to-lead (H2L) is one of the most scientifically demanding phases of small molecule drug discovery. Success depends on far more than identifying active compounds—it requires rapidly optimizing potency, selectivity, physicochemical properties, synthetic feasibility, and future developability through iterative medicinal chemistry. Increasingly, biotechnology companies are outsourcing this stage to specialized discovery partners that combine scientific expertise, efficient Design–Make–Test–Analyze (DMTA) workflows, and integrated chemistry capabilities, enabling internal teams to focus on biological innovation while accelerating candidate generation.

In summary, H2L is critical because it transforms initial hits into balanced drug-like candidates through iterative DMTA cycles, and success depends on efficient learning and experienced medicinal chemistry.

Key Takeaways

• Hit-to-lead optimization determines whether an initial screening hit can realistically become a preclinical development candidate.

• Modern biotechnology companies increasingly outsource medicinal chemistry to complement lean internal research teams rather than simply expand laboratory capacity.

• Successful outsourcing depends on scientific collaboration, rapid learning cycles, and integrated chemistry expertise—not laboratory size alone.

• Early consideration of synthetic accessibility and future development requirements reduces downstream risk and improves project efficiency.

Why Is Hit-to-Lead the Most Critical Stage of Small Molecule Drug Discovery?

Every approved small molecule medicine began as a biological hypothesis, yet only a small fraction of early screening hits ultimately become development candidates. The reason lies in the complexity of hit-to-lead optimization.

At this stage, the scientific question changes fundamentally. Researchers are no longer asking whether a molecule interacts with a biological target. Instead, they are evaluating whether that molecule can evolve into a drug with the balance of properties required for successful development.

Achieving that balance is rarely straightforward. Improving target affinity may reduce solubility. Increasing metabolic stability may compromise permeability. Structural modifications that enhance selectivity can also introduce synthetic complexity or create manufacturing challenges later in development. Rather than optimizing one property at a time, medicinal chemists continuously weigh competing objectives to improve the overall profile of a compound series.

This iterative optimization process forms the core of modern hit-to-lead research. Each Design–Make–Test–Analyze (DMTA) cycle generates new structure–activity relationship (SAR) knowledge, allowing project teams to refine molecular hypotheses based on experimental evidence instead of intuition alone. Recent advances in high-throughput experimentation, reaction prediction, and AI-assisted molecular design are accelerating these learning cycles, but experienced medicinal chemistry remains central to interpreting data and making informed design decisions.

Why Are More Biotech Companies Outsourcing Hit-to-Lead Discovery?

The way innovative medicines are discovered has changed significantly over the past decade.

Many emerging biotechnology companies now operate with compact, highly specialized research teams. Their competitive advantage often lies in disease biology, target validation, or translational science rather than maintaining large medicinal chemistry departments. As a result, outsourcing has evolved from a procurement decision into an extension of scientific strategy.

Instead of investing heavily in internal chemistry infrastructure, companies increasingly partner with external discovery organizations that provide medicinal chemistry expertise, synthetic chemistry, and chemistry development within an integrated project environment. This approach allows internal scientists to remain focused on biological decision-making while expanding chemistry capacity as programs advance.

The motivation extends beyond operational flexibility. Investors expect shorter development timelines, and early-stage companies often manage multiple discovery programs simultaneously. External partnerships make it possible to scale chemistry resources efficiently without compromising scientific quality or creating long-term fixed costs.

Outsourcing is particularly valuable when organizations need to:

Project Scenario	Why Outsourcing Creates Value
Virtual or early-stage biotech	Immediate access to experienced medicinal chemistry teams without building internal infrastructure
Multiple discovery programs running in parallel	Flexible chemistry capacity that scales with project demand
Aggressive IND or financing milestones	Faster DMTA cycles supported by coordinated project management
Complex synthetic chemistry challenges	Access to specialized synthetic expertise and enabling chemistry technologies
Programs expected to progress into development	Better continuity between discovery chemistry and later-stage chemistry development

The strongest partnerships do not replace internal scientific leadership. Instead, they extend it by contributing complementary expertise, accelerating experimental learning, and supporting more confident project decisions.

What Does a Successful Hit-to-Lead Workflow Look Like?

Although every discovery program follows its own scientific path, successful hit-to-lead campaigns typically share a common objective: transforming validated screening hits into chemically tractable lead series with realistic development potential.

The process usually begins with hit confirmation, where initial screening results are verified through orthogonal biological assays and analytical characterization. Confirmed hits are then evaluated for novelty, intellectual property potential, and synthetic accessibility before significant chemistry resources are committed.

The next stage focuses on structure–activity relationship (SAR) exploration. Rather than generating large numbers of random analogues, medicinal chemists design compounds to answer specific scientific questions. Small modifications to stereochemistry, heterocycles, substituents, or functional groups gradually reveal how molecular structure influences biological performance.

Throughout successive optimization cycles, SAR guides improvements across multiple parameters, including target potency, selectivity, metabolic stability, solubility, permeability, and synthetic tractability. Because these properties frequently compete with one another, successful optimization depends on balancing the overall molecular profile rather than maximizing any single experimental result.

An increasingly important aspect of modern H2L programs is the early assessment of developability. Instead of postponing manufacturing considerations until later development stages, many discovery teams now evaluate synthetic scalability, route robustness, and physicochemical properties during hit-to-lead optimization. Identifying potential risks early helps reduce downstream attrition and shortens the transition toward preclinical candidate selection.

Core takeaway: a successful workflow integrates hit confirmation, SAR exploration, and early developability assessment to reduce downstream attrition and enable smoother progression.

What Should You Look for in a Hit-to-Lead Discovery Partner?

Selecting a discovery partner is rarely about choosing the largest CRO or the lowest quotation. By the time a project enters hit-to-lead optimization, every design cycle has the potential to influence patent strategy, candidate quality, development timelines, and ultimately the probability of clinical success.

For this reason, experienced biotechnology companies increasingly evaluate outsourcing partners by their scientific contribution rather than their laboratory capacity.

A high-performing partner should not simply synthesize requested compounds. Instead, the team should actively participate in problem-solving, challenge scientific assumptions when appropriate, and contribute ideas that improve the overall discovery strategy.

Several characteristics consistently distinguish successful hit-to-lead collaborations.

Scientific Expertise Should Extend Beyond Synthetic Chemistry

Medicinal chemistry sits at the center of hit-to-lead optimization, but successful programs depend on much more than synthetic execution.

Each analogue should be designed to answer a clear scientific question. Whether the objective is improving target selectivity, increasing metabolic stability, reducing lipophilicity, or simplifying a synthetic route, every structural modification should be supported by a well-defined hypothesis and validated experimentally.

This hypothesis-driven approach allows project teams to learn from every DMTA cycle, gradually transforming isolated experimental observations into actionable SAR knowledge.

Equally important is the ability to recognize when chemistry is no longer the limiting factor. In many discovery programs, biological understanding, assay design, or molecular property optimization—not synthetic capability—becomes the primary challenge. An experienced discovery team understands how these disciplines interact and adjusts project priorities accordingly.

Integration Creates Faster Learning Cycles

One of the most significant changes in modern drug discovery is the shift from sequential workflows to integrated scientific collaboration.

Historically, medicinal chemistry, analytical chemistry, process chemistry, and project management often operated independently. Today, the most productive discovery teams bring these functions together from the earliest stages of optimization.

When chemists, analytical scientists, and project managers work within a coordinated workflow, experimental feedback reaches the design team more quickly, enabling faster decision-making and reducing unnecessary synthesis.

For biotechnology companies operating under investor milestones or aggressive IND timelines, shortening learning cycles often creates more value than simply increasing synthesis throughput.

Why Should Development Thinking Should Begin During Discovery

An effective hit-to-lead strategy does not end with identifying a potent compound.

Discovery decisions should also support future development.

For example, introducing multiple chiral centers or highly specialized building blocks may improve biological activity but substantially increase synthetic complexity. Likewise, an attractive lead series may ultimately prove impractical if raw materials are difficult to source or scalable chemistry cannot be established.

Considering these factors during hit-to-lead optimization helps reduce technical risk later in development and creates a smoother transition toward preclinical candidate selection.

This development-oriented perspective is becoming increasingly important as biotechnology companies seek to accelerate timelines without compromising long-term manufacturability.

What Should a Practical Checklist for Evaluating a Discovery Partner

When comparing outsourcing partners, technical capability should be evaluated as an integrated system rather than a collection of individual services.

The following questions provide a practical framework for early assessment.

Evaluation Area	Key Questions to Ask
Medicinal Chemistry	Does the team have experience across diverse target classes and complex molecular scaffolds?
Synthetic Capability	Can they solve challenging chemistry involving stereochemistry, fluorinated compounds, macrocycles, or heterocyclic synthesis?
Project Management	Are communication, milestone tracking, and scientific discussions efficient and transparent?
Analytical Support	Can compound identity and quality be confirmed rapidly and consistently?
Scalability	Can promising compounds be prepared beyond milligram quantities as programs advance?
Long-Term Collaboration	Can the same organization continue supporting chemistry during later development stages if required?

Rather than viewing these capabilities independently, sponsors should evaluate how effectively they function together within a single discovery program.

Industry Trends Reshaping Hit-to-Lead Discovery

The scientific principles underlying medicinal chemistry remain remarkably consistent, but the tools available to discovery teams are evolving rapidly.

Several trends are reshaping how successful hit-to-lead programs are executed.

Faster DMTA Cycles Are Becoming a Competitive Advantage

Across the pharmaceutical industry, organizations are investing in technologies that accelerate Design–Make–Test–Analyze workflows.

High-throughput experimentation (HTE), automated reaction screening, digital laboratory platforms, and predictive computational tools all contribute to faster iteration and more informed decision-making.

The objective is not simply to synthesize more compounds.

It is to learn more from every experimental cycle.

Organizations capable of rapidly integrating chemistry, analytical results, and biological feedback are generally able to progress discovery programs more efficiently than those relying on disconnected workflows.

Discovery Platforms Are Becoming More Connected

Another notable industry trend is the growing preference for integrated discovery platforms.

Rather than coordinating multiple service providers for medicinal chemistry, synthetic chemistry, chemistry development, and later-stage support, many biotechnology companies now seek partners capable of maintaining scientific continuity throughout the lifecycle of a project.

This integrated approach reduces technology transfer, preserves project knowledge, simplifies communication, and minimizes delays as promising programs move from discovery toward development.

For emerging biotechnology companies with limited internal infrastructure, this continuity has become an increasingly important consideration when selecting an external partner.

Experience in Practice: Scientific Partnership Beyond Compound Synthesis

Scientific capability is best demonstrated through real project experience rather than broad capability statements. While every discovery program presents unique technical challenges, successful projects often share one characteristic: they balance innovative medicinal chemistry with a clear pathway toward future development.

ChemExpress has built its small molecule discovery platform around this philosophy. The platform supports projects from Hit Identification and Lead Optimization through Preclinical Candidate Development and IND Compound Generation, offering both Fee-for-Service (FFS) and Full-Time Equivalent (FTE) collaboration models to accommodate different R&D strategies.

Over the past several years, the discovery team has contributed to more than 70 medicinal chemistry projects, spanning over 20 signaling pathways and hundreds of biological targets. This experience has exposed scientists to a wide variety of target classes, molecular scaffolds, and optimization strategies, providing a broad technical foundation for early-stage discovery programs.

To improve chemistry efficiency, the platform also incorporates enabling technologies such as High-Throughput Experimentation (HTE), flow chemistry, and biocatalysis where appropriate. These technologies are not intended to replace traditional medicinal chemistry; instead, they expand the range of synthetic solutions available for challenging optimization projects and help accelerate experimental learning within DMTA workflows.

More importantly, the discovery platform is designed with continuity in mind. As promising lead series advance, project teams can continue working within the same scientific environment rather than transferring chemistry activities between multiple organizations. Maintaining this continuity preserves project knowledge, simplifies communication, and reduces operational complexity as programs move toward development.

Discovery Decisions Shape Future Development

One lesson repeatedly observed across the pharmaceutical industry is that development challenges often originate during discovery.

A lead compound with excellent biological activity may still encounter significant obstacles if its synthetic route is difficult to reproduce, impurities become difficult to control, or key intermediates cannot be manufactured reliably at larger scale.

For this reason, experienced medicinal chemists increasingly evaluate more than biological performance during hit-to-lead optimization. Synthetic accessibility, route robustness, raw material availability, and future manufacturability are becoming integral parts of compound selection rather than considerations reserved for process development.

This broader perspective helps reduce downstream technical risk while supporting a smoother transition from discovery into development.

A Practical Example of Development-Oriented Chemistry

A ChemExpress case study on Eribulin API development illustrates how development thinking shapes complex chemistry projects from the earliest stages.

During the process development of Eribulin API, one of the most structurally complex marketed small-molecule anticancer drugs, the team addressed substantial synthetic challenges associated with a molecule containing 19 stereogenic centers and a 62-step synthetic sequence. Maintaining stereochemical integrity, controlling impurities, and improving process reproducibility required careful optimization across multiple stages of synthesis.

The project successfully completed 100 g GMP process verification while maintaining characteristic impurities within stringent quality specifications and supporting subsequent regulatory documentation.

Although this project belongs to the development stage rather than hit-to-lead discovery, it highlights an important principle that also applies much earlier in drug discovery:

Key Principle: The most effective medicinal chemistry strategies anticipate future development requirements instead of optimizing biological activity alone.

When discovery scientists understand how today's molecular design decisions may influence tomorrow's process chemistry, projects are better positioned for long-term success.

How Is ChemExpress Is Positioned to Support Early Discovery Programs

Every biotechnology company has different scientific priorities. Some require dedicated medicinal chemistry support for a single lead series, while others need a flexible partner capable of adapting as projects evolve.

Rather than offering isolated chemistry services, ChemExpress has established an integrated small molecule discovery platform that supports key stages of early drug discovery within a coordinated project framework. Publicly available information indicates that the platform covers Hit Identification, Lead Optimization, Preclinical Candidate Development, and IND Compound Generation, allowing sponsors to engage scientific resources according to the maturity of each program.

The emphasis is not simply on compound delivery. Equally important is close scientific communication throughout the optimization process. By combining medicinal chemistry expertise with enabling chemistry technologies and development-oriented thinking, project teams can iterate more efficiently, evaluate emerging SAR with greater confidence, and maintain continuity as discovery programs mature.

For biotechnology companies seeking a long-term scientific collaborator rather than a transactional service provider, this integrated approach can reduce project complexity while supporting faster and more informed decision-making.

FAQ

1. What is the difference between hit identification, hit-to-lead, and lead optimization?

Hit identification, hit-to-lead (H2L), and lead optimization (LO) are three sequential and distinct stages of early small molecule drug discovery, each with different scientific objectives. Although these terms are often used together, understanding where one ends and the next begins is essential for planning outsourcing partnerships and setting realistic project expectations.

Hit identification focuses on discovering compounds with measurable biological activity through approaches such as high-throughput screening (HTS), fragment-based drug discovery (FBDD), DNA-encoded library (DEL) screening, virtual screening, or structure-based design.

Hit-to-lead (H2L) transforms confirmed hits into chemically tractable lead series through iterative medicinal chemistry. During this stage, scientists optimize potency, selectivity, physicochemical properties, and early developability while establishing meaningful structure–activity relationships (SAR).

Lead optimization (LO) further refines selected lead compounds to achieve the balance of efficacy, pharmacokinetics, safety, and manufacturability required for preclinical candidate nomination.

Although these stages have different objectives, they increasingly operate as a continuous learning process driven by rapid DMTA cycles and multidisciplinary scientific collaboration.

2. Why are biotechnology companies outsourcing hit-to-lead discovery?

Biotechnology companies outsource hit-to-lead discovery primarily to access experienced medicinal chemistry expertise rapidly, reduce fixed infrastructure costs, and maintain competitive timelines across multiple programs simultaneously. For many biotechnology companies, outsourcing is no longer simply a way to increase laboratory capacity.

Modern biotech organizations often build their competitive advantage around disease biology, novel targets, or translational science while maintaining relatively lean chemistry teams. Outsourcing allows them to rapidly access experienced medicinal chemists, flexible scientific resources, and established discovery workflows without making large investments in internal infrastructure.

Equally important, external discovery partners can provide additional scientific perspectives that help accelerate decision-making and reduce technical risk during one of the most challenging stages of drug discovery.

3. How long does a typical hit-to-lead program take?

A typical hit-to-lead program takes approximately 6–18 months, depending on target complexity, hit quality, and optimization objectives. There is no universal timeline because every project begins with different chemistry, biology, and development requirements.

Highly validated targets with well-characterized chemical series may progress more rapidly, while programs involving novel scaffolds or difficult physicochemical profiles may require longer optimization cycles.

Project duration is influenced by several factors, including:

• Quality of the initial hit series.

• Complexity of medicinal chemistry optimization.

• Availability of biological assays.

• Speed of experimental feedback.

• Synthetic accessibility.

• Development objectives.

Organizations that combine efficient project management with rapid DMTA workflows are generally better positioned to shorten overall discovery timelines.

4. What should companies look for when choosing a medicinal chemistry partner?

The most important criteria for selecting a medicinal chemistry CRO partner are demonstrated scientific expertise across diverse target classes, integrated DMTA workflow capability, transparent communication, and the ability to maintain project continuity from discovery into development. An effective discovery partner contributes scientific insight rather than simply delivering synthesized compounds.

Equally important is understanding where outsourced partnerships tend to fall short. Common reasons hit-to-lead programs underperform include insufficient scientific communication between sponsor and partner, misaligned expectations around development readiness, and overemphasis on synthesis throughput at the expense of DMTA cycle quality. Selecting a partner who actively participates in scientific problem-solving—rather than executing requests passively—is the single most reliable way to avoid these failure modes.

When evaluating potential collaborators, biotechnology companies should consider:

• Demonstrated medicinal chemistry expertise across multiple target classes.

• Experience with complex synthetic chemistry.

• Transparent scientific communication.

• Reliable analytical support.

• Efficient project management.

• The ability to maintain continuity as projects advance beyond early discovery.

The strongest partnerships are built on shared scientific objectives, frequent technical discussion, and collaborative problem-solving throughout the discovery process.

5. How can ChemExpress support small molecule discovery?

ChemExpress provides integrated small molecule discovery services spanning Hit Identification, Lead Optimization, Preclinical Candidate Development, and IND Compound Generation, enabling biotechnology and pharmaceutical companies to access flexible chemistry resources throughout early drug discovery.

Rather than functioning solely as a synthetic chemistry provider, the platform combines medicinal chemistry expertise with enabling technologies such as High-Throughput Experimentation (HTE), flow chemistry, and biocatalysis, supporting efficient DMTA workflows for challenging discovery programs.

For organizations seeking long-term scientific collaboration, the ability to maintain project continuity from early medicinal chemistry into later chemistry development can help simplify technology transfer and support more efficient progression toward development.

References

small molecule drug discovery hit-to-lead optimization medicinal chemistry outsourcing lead optimization drug discovery services

News & Events